Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
Tirzepatide: research-grade sample of a dual GIP/GLP-1 agonist, RUO, lyophilized, COA per LOT. Not Mounjaro, not Zepbound. The molecule, not the brand.
Size: 5 mg
No published analyses yet.
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start (weeks 1–4) | 2.5 mg weekly | Starting dose |
| Titration | 5 → 7.5 → 10 → 12.5 mg weekly | +2.5 mg every 4 weeks if needed |
| Maximum | 15 mg weekly | Maximum in this schedule |
FAQ
Find answers to questions about Tirzepatide and related materials.
A sealed lyophilized vial is stored at -20 °C, protected from light and moisture: in that state the dry powder is stable for months to years. That differs from storing the already reconstituted solution (2–8 °C, a few weeks). See the full storage and lab-handling breakdown on the documentation page /en/docs/tirzepatide.
Source / documentationTirzepatide comes in three package sizes: 5 mg, 30 mg, and 120 mg. Pick the one you need in the size selector above.
Source / documentationThe reconstituted solution should be stored at 2–8 °C. Detailed storage conditions and shelf-life after reconstitution are provided on the label and in the LOT technical documentation.
Source / documentationNo. Tirzepatide from Longeva is a research molecule, not a brand name. It is neither Mounjaro (a pharmaceutical drug) nor Zepbound (a brand name), but a pure research sample for laboratory purposes.
Source / documentationRUO means the product is intended exclusively for scientific research in laboratory settings. Tirzepatide from Longeva is not a medicine and is not permitted for clinical use or human application.
Source / documentationTirzepatide is supplied as a lyophilized powder, which ensures molecular stability during storage and ease of reconstitution for research applications.
Source / documentationBatches of Tirzepatide are tested by independent third-party laboratories, and we publish the reports in the open COA archive. Check the current list of reports for this substance at /coa?q=tirzepatide to see which batches already have a published certificate.
Source / documentationTirzepatide is a research molecule, a synthetic dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. For a full breakdown of the receptors, mechanism, and weekly profile, see the wiki reference: /wiki/tirzepatide.
Source / documentationThe half-life of tirzepatide is approximately 5 days. The figure is stated in both the FDA and EMA labels; a population pharmacokinetic analysis across 5,802 participants gives a half-life of 5.4 days. See the Dosing section for detail.
Source / documentation1 review
Беру постоянно тут работает, фото не могу приложуть а то баг на сайте, исправлю как пройдет
In brief: Tirzepatide (INN: tirzepatide) from Longeva is a research sample supplied as a lyophilized powder, intended for laboratory research (RUO). On this page you can pick a fill size, check availability and price, and open the batch documents. It is not Mounjaro, not Zepbound, and not a finished prescription medicine.
Batches of Tirzepatide are tested by independent third-party laboratories; we publish the reports in the open archive as they come in. A report confirms the analytics at the time of testing, not the medical status of the material.
Tirzepatide is described as a synthetic dual agonist of the GIP and GLP-1 receptors. Clinical programmes studied it in controlled protocols, among them SURPASS for glycaemic control in type 2 diabetes and SURMOUNT for body weight control (SURPASS-2 and SURMOUNT-1 design breakdown). This is mechanistic context for the class, not a promise of an effect from an RUO vial.
Mounjaro and Zepbound are trademarks of finished injectable medicines containing tirzepatide. They are registered as medicinal products and belong to a different product class than an RUO lyophilizate. Tirzepatide is the name of the active substance; Mounjaro and Zepbound are trade names of the medicines that contain it (more on the brand and the molecule). Longeva does not manufacture, sell, or represent these brands.
Tirzepatide activates both the GIP and GLP-1 receptors, while semaglutide acts on GLP-1 alone. These are different molecules with different receptor profiles, not two versions of the same one. For a detailed comparison of trial design and pharmacokinetics, see the tirzepatide vs semaglutide article.
The sample ships as a lyophilized powder in a glass vial. Storage conditions differ substantially between a sealed vial and an already reconstituted solution. The full breakdown, including lab handling, is on the documentation page "Tirzepatide: form, reconstitution and lab handling".
The wiki reference describes the molecule's properties and research data: the receptors, the mechanism of action, the weekly profile, not a specific vial. Fill size, availability, and RUO status are covered by this product card. Results for a specific batch are reported in its COA: the report states the sample tested, the methods applied, and the results obtained. Quantitative content is stated only when that measurement was actually performed.
| Topic | Resource |
|---|---|
| Mechanism of action and research | molecule reference (wiki) |
| Form, reconstitution, storage | batch documentation |
| Batch verification, COA results | COA archive |
Reference material. Not medical advice. The sample is intended for laboratory research only (RUO). Mounjaro, Zepbound, Ozempic, Saxenda and other names mentioned are trademarks of their respective owners.
Buy 2, get the 3rd free
The set contains two vials of 120 mg.
240 mg: Best value · Save ≈ $84.34
